Physicians should not only avoid forming personal relationships with drug reps but must also acquire and apply numeracy skills and information management strategies to critically evaluating drug reps’ information.
AMA J Ethics. 2015;17(8):729-733. doi:
10.1001/journalofethics.2015.17.8.ecas1-1508.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.